title: Hepatotoxicity due to etanercept abated after dose reduction in a patient with pustular psoriasis and without compromised efficacy.
authors.forename: Zhengxiao
authors.initials: Z
authors.lastname: Li
authors.forename: Shengxiang
authors.initials: S
authors.lastname: Xiao
authors.forename: Jianwen
authors.initials: J
authors.lastname: Ren
authors.forename: Yanfei
authors.initials: Y
authors.lastname: Zhang
authors.forename: Chen
authors.initials: C
authors.lastname: Tu
authors.forename: Fanpu
authors.initials: F
authors.lastname: Ji
mesh_terms: D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D056486:Chemical and Drug Induced Liver Injury / Q000628:therapy*; D000068800:Etanercept / Q000009:adverse effects* / Q000627:therapeutic use*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D008297:Male; D011565:Psoriasis / Q000150:complications* / Q000188:drug therapy*
chemical_list: D007166:Immunosuppressive Agents; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D000068800:Etanercept